Dieter Morszeck Foundation: Outstanding commitment to the German Cancer Research Center

August 09, 2018 - 10:54

Cologne entrepreneur Dieter Morszeck, former CEO and owner of RIMOWA, donated part of his assets to the RIMOWA Dieter Morszeck Foundation in 2017. The foundation has three major focuses of which support for cancer research is...» [more]

» [more]

IASP meeting in Romania: IASP advises new science park project in Romania

June 20, 2018 - 09:00

IASP European Division President André Domin (Heidelberg Technology Park, Germany) travelled to Romania to address the ‘Inventing The Future’ event which presented Magurele Science Park to over 200 representatives from academia,...» [more]

» [more]

Press Release {Life Sience} meets IT Hackathon

June 18, 2018 - 12:32

Hackathon, 8-10 June at MAFINEX Technologiezentrum Mannheim» [more]

» [more]

How does medicine get from research to the patient’s bedside? Heidelberg Technology Park organizes an exchange with international players in Boston

June 06, 2018 - 11:52

Heidelberg Technology Park hosts its traditional Breakfast Session at the BIO International Convention, the biggest biotechnology convention in the world. As part of a joint breakfast at the renowned Boston law firm Cooley, 30...» [more]

» [more]

EC and EMA provide Brexit guidance

June 09, 2017 - 09:43

UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location...» [more]

» [more]

SYGNIS AG announces management changes

June 09, 2017 - 09:38

Co-CEO Pilar de la Huerta to resign from the management board and to transition to the supervisory board. SYGNIS AG announced on June 5, 2017 changes to the management team. Pilar de la Huerta resigned from her position as...» [more]

» [more]

Seal of quality for the Heidelberg Technology Park

December 19, 2016 - 16:01

The Federal German association of innovation, technology and business incubation centres (BVIZ), awarded the Heidelberg Technology Park (TP) the quality seal “Recognised Innovation Centre”. Whether a start-up, a technology...» [more]

» [more]

Mini-Accelerator “what's next?” prepares 13 life science teams for starting up a company

December 19, 2016 - 16:10

Four-week program prepared life science teams for the concrete challenges of starting up a company. Topics ranged from the limited liability company statute and investor contracts, through leadership skills and personnel...» [more]

» [more]

Development of the Technology Park from 1984 onward

December 19, 2016 - 15:50

Part 2: A look at the space from 2010 up till the near future» [more]

» [more]

Californian pioneering spirit inspires Heidelberg technology sponsor

December 19, 2016 - 15:40

At the beginning of November, Mayor Prof. Eckart Würzner spent two days visiting partners in Palo Alto and San Francisco (SF) together with four members of the municipal council from the CDU (Dr. Jan Gradel), The Greens (Felix...» [more]

» [more]

TP CEO elected European Division President of the IASP

December 19, 2016 - 15:35

The International Association of Science Parks and Areas of Innovation (IASP) is an association of technology parks and high-tech clusters. It promotes the exchange of information, people and technologies at an international...» [more]

» [more]

RegioWIN promotes innovations in Heidelberg

December 19, 2016 - 15:20

The Rhine-Neckar Metropolitan Region (MRN) won two flagship projects in the state competition RegioWIN in 2015.» [more]

» [more]

“Every day is a new challenge.”

December 19, 2016 - 15:08

Biomeva manufactures active substances for clinical trials» [more]

» [more]

Apogenix Reports Significant Progress in Collaboration with CANbridge

November 04, 2016 - 17:07

First Asian Clinical Trial with Asunercept (APG101) Initiated in Glioblastoma Patients» [more]

» [more]

Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition

November 03, 2016 - 16:50

Final Phase I trial data with APG101 in myelodysplastic syndromes to be presented CD95-ligand inhibitor APG101 with novel mechanism of action and potential to treat disease in a new way» [more]

» [more]

Displaying results 1 to 15 out of 64
<< First < Previous 1-15 16-30 31-45 46-60 61-64 Next > Last >>